Ries M - Search Results

1

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, Pastores GM, Kampmann C, Ries M, Clarke JT. Schiffmann R, et al. Among authors: ries m. J Pediatr. 2010 May;156(5):832-7, 837.e1. doi: 10.1016/j.jpeds.2009.11.007. Epub 2010 Jan 25. J Pediatr. 2010. PMID: 20097359 Clinical Trial.

2

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R. Ries M, et al. Pediatrics. 2006 Sep;118(3):924-32. doi: 10.1542/peds.2005-2895. Pediatrics. 2006. PMID: 16950982 Clinical Trial.

3

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P. Schiffmann R, et al. Among authors: ries m. Genet Med. 2013 Dec;15(12):983-9. doi: 10.1038/gim.2013.56. Epub 2013 May 16. Genet Med. 2013. PMID: 23680766 Free article. Clinical Trial.

4

A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease.

Schiffmann R, Swift C, Wang X, Blankenship D, Ries M. Schiffmann R, et al. Among authors: ries m. J Inherit Metab Dis. 2015 Nov;38(6):1129-36. doi: 10.1007/s10545-015-9845-5. Epub 2015 Apr 22. J Inherit Metab Dis. 2015. PMID: 25900714 Clinical Trial.

5

Fabry Disease: A Disorder of Childhood Onset.

Schiffmann R, Ries M. Schiffmann R, et al. Among authors: ries m. Pediatr Neurol. 2016 Nov;64:10-20. doi: 10.1016/j.pediatrneurol.2016.07.001. Epub 2016 Jul 29. Pediatr Neurol. 2016. PMID: 27555236 Review.

6

Pediatric Fabry disease.

Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R. Ries M, et al. Pediatrics. 2005 Mar;115(3):e344-55. doi: 10.1542/peds.2004-1678. Epub 2005 Feb 15. Pediatrics. 2005. PMID: 15713906

7

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.

Gupta S, Ries M, Kotsopoulos S, Schiffmann R. Gupta S, et al. Among authors: ries m. Medicine (Baltimore). 2005 Sep;84(5):261-268. doi: 10.1097/01.md.0000178976.62537.6b. Medicine (Baltimore). 2005. PMID: 16148726 Free article.

8

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Schiffmann R, et al. Among authors: ries m. Nephrol Dial Transplant. 2006 Feb;21(2):345-54. doi: 10.1093/ndt/gfi152. Epub 2005 Oct 4. Nephrol Dial Transplant. 2006. PMID: 16204287 Clinical Trial.

9

Fabry's disease--an important risk factor for stroke.

Schiffmann R, Ries M. Schiffmann R, et al. Among authors: ries m. Lancet. 2005 Nov 19;366(9499):1754-6. doi: 10.1016/S0140-6736(05)67636-2. Lancet. 2005. PMID: 16298202 No abstract available.

10

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R. Ries M, et al. J Clin Pharmacol. 2007 Oct;47(10):1222-30. doi: 10.1177/0091270007305299. Epub 2007 Aug 13. J Clin Pharmacol. 2007. PMID: 17698592 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

648 results

Search Page